Polaryx Therapeutics, Inc. PLYX Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Polaryx Therapeutics, Inc. 's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's business segments — stock-based comp?
- Polaryx Therapeutics, Inc. (PLYX) reported business segments — stock-based comp of $467K in Q1 2026.
- How has Polaryx Therapeutics, Inc. 's business segments — stock-based comp changed year-over-year?
- Polaryx Therapeutics, Inc. 's business segments — stock-based comp decreased by 89.5% year-over-year, from $4.45M to $467K.
- What does business segments — stock-based comp mean?
- This metric represents the non-cash expense recognized for equity-based awards granted to employees and consultants working within the lysosomal storage disorders segment. It reflects the cost of talent retention and alignment of incentives with shareholder interests through stock options or restricted stock units. Investors use this to understand the true cost of human capital and potential dilution within this specific business unit.